Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Monthly Prescribing Reference

Zoryve Foam 0.3% Approved for Plaque Psoriasis of the Scalp, Body

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...
Healio

Tremfya outperforms IL-17 inhibitors in treatment persistence for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tremfya showed greater persistence in bio-naïve and ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that ...
Healio

Phase 3, real-world data show deucravacitinib efficacious for scalp, overall psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Deucravacitinib maintained efficacy and safety when ...
clinicaladvisor.com

From Symptoms to Solutions: A Look at Systemic Treatments for Moderate to Severe Plaque Psoriasis

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...
CBS News

One mechanic navigates life with moderate to severe plaque psoriasis

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...
Nasdaq

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...
clinicaladvisor.com

Biologic Drug Therapy in Severe Plaque Psoriasis With New-Onset Joint Pain

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...
Essence

Living with Plaque Psoriasis as a Black Woman Isn’t Easy: Alisha Bridges Won’t Let the Disease Define Her

Alisha Bridges, 36, knows what it feels like to be treated differently because of how she looks. Since elementary school, Alisha has struggled with severe plaque psoriasis—a condition which causes ...
The National Law Review

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...